{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:04:11Z","timestamp":1791821051160,"version":"4.3.4"},"reference-count":9,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":3122,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"\n OBJECTIVE<\/jats:title>\n A 12-week study assessed the efficacy and safety of a new oral antidiabetic agent, imeglimin, as add-on therapy in type 2 diabetes patients inadequately controlled with metformin alone.<\/jats:p>\n <\/jats:sec>\n \n RESEARCH DESIGN AND METHODS<\/jats:title>\n A total of 156 patients were randomized 1:1 to receive imeglimin (1,500 mg twice a day) or placebo added to a stable dose of metformin (1,500\u20132,000 mg\/day). Change in A1C from baseline was the primary efficacy outcome; secondary outcomes included fasting plasma glucose (FPG) and proinsulin\/insulin ratio.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n After 12 weeks, the placebo-subtracted decrease in A1C with metformin-imeglimin was \u22120.44% (P &lt; 0.001). Metformin-imeglimin also significantly improved FPG and the proinsulin\/insulin ratio from baseline (\u22120.91 mg\/dL and \u22127.5, respectively) compared with metformin-placebo (0.36 mg\/dL and 11.81). Metformin-imeglimin therapy was generally well-tolerated with a comparable safety profile to metformin-placebo.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n Addition of imeglimin to metformin improved glycemic control and offers potential as a new treatment for type 2 diabetes.<\/jats:p>\n <\/jats:sec>","DOI":"10.2337\/dc12-0453","type":"journal-article","created":{"date-parts":[[2012,11,17]],"date-time":"2012-11-17T04:52:46Z","timestamp":1353127966000},"page":"565-568","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":87,"title":["The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy"],"prefix":"10.2337","volume":"36","author":[{"given":"Pascale","family":"Fouqueray","sequence":"first","affiliation":[{"name":"Poxel SA, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdis","family":"Pirags","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Paul Stradins Clinical University Hospital, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford J.","family":"Bailey","sequence":"additional","affiliation":[{"name":"School of Life and Health Sciences, Aston University, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guntram","family":"Schernthaner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rudolfstiftung Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Diamant","sequence":"additional","affiliation":[{"name":"Diabetes Center\/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E.","family":"Lebovitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, State University of New York, Health Sciences Center, Brooklyn, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,2,13]]},"reference":[{"key":"2022031302210744900_B1","first-page":"4","article-title":"Imeglimin\u2013a new oral anti-diabetic that targets the three key defects of type 2 diabetes","volume-title":"J Diabetes Metab","author":"Fouqueray","year":"2011"},{"key":"2022031302210744900_B2"},{"key":"2022031302210744900_B3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"Recommendations guiding physicians in biomedical research involving human subjects","volume":"277","author":"World Medical Association Declaration of Helsinki","year":"1997","journal-title":"JAMA"},{"key":"2022031302210744900_B4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2337\/dc11-S011","article-title":"Standards of medical care in diabetes - 2011","volume":"34","author":"American Diabetes Association","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031302210744900_B5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031302210744900_B6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0029-1234042","article-title":"Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-na\u00efve patients with type 2 diabetes","volume":"41","author":"Foley","year":"2009","journal-title":"Horm Metab Res"},{"key":"2022031302210744900_B7","unstructured":"Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors [article online], 2011. Available from http:\/\/aace.metapress.com\/content\/p03r8r6026448w8k\/fulltext.pdf. Accessed 8 November 2011"},{"key":"2022031302210744900_B8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","article-title":"Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Gomis","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031302210744900_B9","doi-asserted-by":"crossref","unstructured":"Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral anti-diabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab [article online], 2012. Available from http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1463-1326.2012.01611.x\/pdf Accessed 24 May 2012","DOI":"10.1111\/j.1463-1326.2012.01611.x"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/3\/565\/614650\/565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/3\/565\/614650\/565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T06:32:34Z","timestamp":1647153154000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/3\/565\/38172\/The-Efficacy-and-Safety-of-Imeglimin-as-Add-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,13]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,2,13]]},"published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-0453","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,13]]}}}